Taiwanese Pharmaceuticals & Biotech Mid-Large Cap Stocks

Bora Pharmaceuticals

Market Cap: NT$59.9b

Engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally.

Lotus Pharmaceutical

Market Cap: NT$51.6b

Engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally.

TLC BioSciences

Market Cap: NT$37.4b

Operates as a clinical-stage biotechnology company that develops and sells lipid-engineered medicines in Taiwan, the United States of America, Europe, and the Cayman Islands.

Pell Bio-Med Technology

Market Cap: NT$88.8b

A biomedical company, engages in the research, development, manufacturing, and sales of chimeric antigen recombinant T cell (CAR-T), and other related services and products.

Caliway Biopharmaceuticals

Market Cap: NT$164.1b

Engages in the development of drugs for aesthetic medicine and chronic inflammation.

PharmaEssentia

Market Cap: NT$617.5b

A biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan.

Lin BioScience

Market Cap: NT$77.8b

A drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases.